Interesting to see, how Qiagen recently has had (unusual) prominent coverage in US-publications:

-Last weekend it figured as (positive) front-page story of BioCentury (the "gold standard"-publication when it comes to investing in the biotech space)

-This week there is an equally positive and prominently placed story in Barron's most read "weekly trader" section.

Of course, we do not learn new stuff from the Barron's story; it basically gives the reason why someone like myself has been an investor since the lows in 2003. BioCentury's article, however, is very informative, since it is based, amongst good research on interviews with CEO Peer Schatz.
Unfortunately BioCentury is not freely accessible on the net (to my knowlegde), therefore links do not help much. One might try a "free trial", I guess something like that does exist (?? try at Biocentury.com?))

FWIW

regards

Dr John